Summary
- There have been some exciting developments in the research around the medicinal potential of psychedelic compounds.
- Despite a potential opportunity for disruption, investors should keenly understand the unique risks to biotechnology plays before investing in the space.
- Given the high-risk present in any given individual name, the approach of investing in an ETF with multiple points of exposure makes sense.
- The Advisor Shares PSIL ETF is my particular choice given its size and an active management approach that should prove lucrative relative to other options.
- Investing in psychedelic companies is incredibly high-risk. Many investors should stay away if they are risk-averse and can't afford to lose the funds.
For further details see:
PSIL: When Investing In Psychedelic Firms, ETFs Are The Safer Route